Home  |  Contact

UniProtKB/Swiss-Prot P11387: Variant p.Asp533Gly

DNA topoisomerase 1
Gene: TOP1
Variant information

Variant position:  533
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Aspartate (D) to Glycine (G) at position 533 (D533G, p.Asp533Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CPT-resistant leukemia.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  533
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  765
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.


Mouse                         NLHP-------ELDGQEYVVEFDFPGKDSIRYYNKVPVEKR

Rat                           NLHP-------ELDGQEYVVEFDFPGKDSIRYYNKVPVEKR

Xenopus laevis                NLFQ-------ELDGQEFVVEFDFPGKDSIRYYNKVPVEKR


Drosophila                    QLHK-------ELNGKENVVVFDFPGKDSIRYYNEVEVEKR

Slime mold                    KLES------------NNTITLDFLGKDSMRYLNTVQIRED

Baker's yeast                 TLKP------------PNTVIFDFLGKDSIRFYQEVEVDKQ

Fission yeast                 TLKP------------PRTVVFDFLGKDSIRYYNEVEVDPQ

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 2 – 765 DNA topoisomerase 1
Site 532 – 532 Interaction with DNA
Cross 549 – 549 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)
Mutagenesis 532 – 532 K -> A. Almost abolishes enzyme activity.
Mutagenesis 532 – 532 K -> R. Strongly reduced enzyme activity.
Helix 532 – 534

Literature citations

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.
Tamura H.; Kohchi C.; Yamada R.; Ikeda T.; Koiwai O.; Patterson E.; Keene J.D.; Okada K.; Kjeldsen E.; Nishikawa K.;
Nucleic Acids Res. 19:69-75(1991)

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.